Proteomics International Laboratories Ltd

ASX/Media Release
16 October 2015

ASX code: PIQ

Proteomics International Laboratories Appoints New Director

Life sciences company Proteomics International Laboratories Ltd (ASX: PIQ) (the Company, PILL) is pleased to announce the appointment of Mr James Moses to the Company's board as an executive director, effective from today.

Mr Moses has extensive experience in investment markets and the media developed in a career spanning 25 years, including a wealth of expertise in advising emerging small-cap public companies.

He will work closely with the Company's leadership team to develop and implement appropriate strategies to maximise PILL's awareness and penetration in investment markets and with external stakeholders.

Mr Moses is also the managing director of a leading Australian small-cap focused investor relations and corporate communications practice, and has a successful track record in advising a wide range of companies, including in the life sciences and bio-technology sectors.

His career began in the investment market, where he worked for 15 years in a number of business development roles for leading global fund managers, and as a private client adviser for an investment advisory firm.

Mr Moses, who is based in Sydney, has previously worked as a business and finance journalist, and editor for business and industry publications.

Commenting on the appointment Proteomics International Laboratories chairman Terry Sweet said: *"We welcome James to the Board at this exciting time in the Company's development. His market, media, and investor relations experience will be a great complement to the skill set of our board. We look forward to his positive contributions as we continue to drive company value by accessing new markets and opportunities across our high growth business units."*

In accordance with ASX Listing Rule 3.16.4, the Company provides the following information:

The Company entered into an Executive Services Agreement with Mr Moses to act as an executive director of the Company, commencing on 16 October 2015.

Mr Moses will receive a salary package of $80,000 per annum including statutory superannuation.

The Executive Services Agreement may be terminated without cause by either party giving 3 months' notice.

The Executive Services Agreement otherwise contains terms and conditions which are considered standard in an agreement of this type and is governed by the laws of Western Australia.

ENDS

For further information please contact:
Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com
www.proteomicsinternational.com

Greg Wood
Managing Director
K S Capital
T: +61 416 076 377
E: g.wood@kscapital.com.au

About Proteomics International Laboratories

PILL is an ASX listed (ASX: PIQ) life science company focused on the area of proteomics – the industrial scale study of the structure and function of proteins. Proteomics is an integral part of the biotechnology and life sciences industries and plays a key role in understanding disease and biological systems.

PILL is recognised as a global leader in its field. It received the world's first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the art facilities at the Harry Perkins Institute of Medical Research in Perth, Western Australia. The Company's business model uses its proprietary technology platform which operates across three synergistic proteomics-based business units in massive growth markets:

1. **Diagnostics**: Biomarkers of diseases and personalised medicine - focus on diabetic kidney disease and Alzheimer's disease. The biomarkers market is estimated to double in size to $45.6 billion by 2020.
2. **Analytical services**: Specialist contract research, analytical testing and consultancy - fee for service model. The specialist proteomics market alone represents a massive global market estimated to be worth $20.8 billion by 2018.
3. **Drug discovery**: Therapeutic drug discovery with a focus on painkillers and antibiotics. The peptide therapeutics market is currently estimated to be worth $17 billion.